Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

• Status: Recruiting
• Trial end date: 2025-12-01

Summary

Patients with histologically confirmed gastric adenocarcinoma with locally advanced gastric cancer are randomized in a 1:1 ratio to receive neoadjuvant chemoradiotherapy with DT45Gy/25f plus three cycles of XELOX therapy or neoadjuvant chemotherapy alone using XELOX regimen following D2 gastrectomy and adjuvant chemotherapy for 3 cycles. The primary end point is disease free survival (DFS), and secondary end point is 5-year overall survival (OS), pathological complete remission (pCR) and treatment safety.

• Phase: Phase 3

Details

• Lead Sponsor: Sun Yat-sen University
• Collaborators: First Hospital of China Medical University; First People's Hospital of Hangzhou; Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial People's Hospital; Guangxi Medical University Cancer Center; Liaoning Cancer Hospital & Institute; The First Affiliated Hospital of Anhui Medical University; Tianjin Medical University Cancer Institute & Hospital; Zhejiang Cancer Hospital
• Treatments: Capecitabine; Oxaliplatin